Israel Englander’s Jade Biosciences JBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.99M Buy
314,548
+154,497
+97% +$3.22M ﹤0.01% 2673
2026
Q1
$2.25M Buy
160,051
+97,242
+155% +$1.41M ﹤0.01% 3763
2025
Q4
$969K Buy
+62,809
New +$737K ﹤0.01% 4513
2025
Q2
Sell
-869
Closed -$76.4K 5847
2025
Q1
$76.4K Sell
869
-1,008
-54% -$88.5K ﹤0.01% 5480
2024
Q4
$174K Sell
1,877
-3,741
-67% -$322K ﹤0.01% 5346
2024
Q3
$411K Sell
5,618
-12,723
-69% -$821K ﹤0.01% 4980
2024
Q2
$1.07M Buy
18,341
+16,554
+926% +$11M ﹤0.01% 4069
2024
Q1
$1.85M Buy
+1,787
New +$1.36M ﹤0.01% 3813
2023
Q4
Sell
-1,525
Closed -$724K 6072
2023
Q3
$724K Buy
1,525
+571
+60% +$309K ﹤0.01% 4415
2023
Q2
$573K Buy
954
+360
+61% +$230K ﹤0.01% 4442
2023
Q1
$419K Sell
594
-2,926
-83% -$2.43M ﹤0.01% 4709
2022
Q4
$3.61M Buy
3,520
+1,131
+47% +$821K ﹤0.01% 3077
2022
Q3
$1.39M Buy
2,389
+1,701
+247% +$1.14M ﹤0.01% 4059
2022
Q2
$376K Buy
+688
New +$329K ﹤0.01% 5184
2021
Q4
Sell
-1,996
Closed -$1.47M 6771
2021
Q3
$1.47M Buy
1,996
+138
+7% +$77.3K ﹤0.01% 4260
2021
Q2
$1.49M Buy
+1,858
New +$1.48M ﹤0.01% 4274

Other funds holding JBIO

Israel Englander's JBIO Position: Q2 2026 in Review

Israel Englander increased its Jade Biosciences (JBIO) stake by 97% in Q2 2026, buying an estimated $3.22M and bringing the position to 314,548 shares worth $6.99M. The position accounts for ﹤0.01% of the portfolio, ranked #2673.

Israel Englander first reported a position in JBIO in Q2 2021 and has held it in 16 quarters since. 154 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • Israel Englander held 314,548 shares of Jade Biosciences worth $6.99M as of Q2 2026.
  • Israel Englander bought 154,497 Jade Biosciences shares in Q2 2026, an estimated $3.22M.
  • Jade Biosciences made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2673 holding.
  • Israel Englander first reported a position in Jade Biosciences in Q2 2021 and has held it in 16 quarters since.
  • 154 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.